Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

American Heart Journal

Volumn 169, Issue 6, 2015, Pages 879-889.e7

  Velders, Matthijs A ^a   Wallentin, Lars ^a   Becker, Richard C ^b   Van Boven, Adrianus J ^c   Himmelmann, Anders ^d   Husted, Steen ^e   Katus, Hugo A ^f   Lindholm, Daniel ^a   Morais, Joao ^g   Siegbahn, Agneta ^a   Storey, Robert F ^h   Wernroth, Lisa ^a   James, Stefan K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

^e HOLSTEBRO HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g Cardiology Division Santo Andrés Hospital   (Portugal)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15; TROPONIN T; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ANGIOGRAPHY; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; MYOCARDIAL INFARCTION; PROCEDURES; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; TROPONIN T;

EID: 84930179104     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.02.019     Document Type: Article

References (33)

1. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
2. T. Jernberg, P. Johanson, and C. Held Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction JAMA 305 2011 1677 1684
3. L. Jakobsen, T. Niemann, and N. Thorsgaard Sex- and age-related differences in clinical outcome after primary percutaneous coronary intervention EuroIntervention 8 2012 904 911
4. K.A. Fox, O.H. Dabbous, and R.J. Goldberg Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091
5. D.A. Morrow, E.M. Antman, and A. Charlesworth TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy Circulation 102 2000 2031 2037
6. W.C. Chang, P. Kaul, and Y. Fu Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction Eur Heart J 27 2006 419 426
7. A. Stebbins, R.H. Mehta, and P.W. Armstrong A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial Circ Cardiovasc Interv 3 2010 414 422
8. G. De Luca, H. Suryapranata, and A.W. van 't Hof Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge Circulation 109 2004 2737 2743
9. A. Halkin, M. Singh, and E. Nikolsky Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score J Am Coll Cardiol 45 2005 1397 1405
10. E. Giannitsis, M. Müller-Bardorff, and S. Lehrke Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction Circulation 104 2001 630 635
11. R. Jarai, K. Huber, and K. Bogaerts Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial Am Heart J 159 2010 131 140
12. T. Kempf, E. Björklund, and S. Olofsson Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction Eur Heart J 28 2007 2858 2865
13. S. James, A. Akerblom, and C.P. Cannon Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 157 2009 599 605
14. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
15. K. Thygesen, J.S. Alpert, and H.D. White Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Eur Heart J 28 2007 2525 2538
16. P. Damman, L. Wallentin, and K.A.A. Fox Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR) Circulation 125 2012 568 576
17. E. Giannitsis, K. Kurz, and K. Hallermayer Analytical validation of a high-sensitivity cardiac troponin T assay Clin Chem 56 2010 254 261
18. N. Johnston, T. Jernberg, and B. Lindahl Biochemical indicators of cardiac and renal function in a healthy elderly population Clin Biochem 37 2004 210 216
19. T. Kempf, R. Horn-Wichmann, and G. Brabant Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay Clin Chem 53 2007 284 291
20. M.J. Pencina, and R.B. D'Agostino Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation Stat Med 23 2004 2109 2123
21. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
22. M.J. Leening, M.M. Vedder, and J.C. Witteman Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide Ann Intern Med 160 2014 122 131
23. S. van Diepen, L.K. Newby, and R.D. Lopes Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy Int J Cardiol 168 2013 2127 2133
24. T.G. Kwon, J.H. Bae, and M.H. Jeong N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention Int J Cardiol 133 2009 173 178
25. P. Damman, M.A. Beijk, and W.J. Kuijt Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction J Am Coll Cardiol 57 2011 29 36
26. M.S. Sabatine, D.A. Morrow, and J.A. de Lemos Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia J Am Coll Cardiol 44 2004 1988 1995
27. M.P. Bonaca, D.A. Morrow, and E. Braunwald Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 31 2011 203 210
28. X. Xu, Z. Li, and W. Gao Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside Biomarkers 16 2011 466 475
29. L. Lind, L. Wallentin, and T. Kempf Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study Eur Heart J 30 2009 2346 2353
30. G.W. Stone, A. Maehara, and A.J. Lansky A prospective natural-history study of coronary atherosclerosis N Engl J Med 364 2011 226 235
31. J.J. Goldberger, R.O. Bonow, and M. Cuffe beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing Am Heart J 160 2010 435-442.e1
32. D.S. Wald, J.K. Morris, and N.J. Wald Randomized trial of preventive angioplasty in myocardial infarction N Engl J Med 369 2013 1115 1123
33. L. Wallentin, D. Lindholm, and A. Siegbahn Biomarkers in relation to the effects of ticagrelor compared with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial Circulation 129 2014 293 303